

ESTRO-SIOPE guideline: Clinical management of radiotherapy in atypical teratoid/rhabdoid tumors (AT/RTs)

Beate Timmermann, Claire Alapetite, Karin Dieckmann, Rolf-Dieter Kortmann, Yasmin Lassen-Ramshad, John H. Maduro, Monica Ramos Albiac, Umberto Ricardi, Damien C. Weber

PII: S0167-8140(24)00149-X  
DOI: <https://doi.org/10.1016/j.radonc.2024.110227>  
Reference: RADION 110227


To appear in: *Radiotherapy and Oncology*

Received Date: 8 March 2024  
Accepted Date: 10 March 2024

Please cite this article as: Timmermann, B., Alapetite, C., Dieckmann, K., Kortmann, R-D., Lassen-Ramshad, Y., Maduro, J.H., Ramos Albiac, M., Ricardi, U., Weber, D.C., ESTRO-SIOPE guideline: Clinical management of radiotherapy in atypical teratoid/rhabdoid tumors (AT/RTs), *Radiotherapy and Oncology* (2024), doi: <https://doi.org/10.1016/j.radonc.2024.110227>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier B.V.



# **ESTRO-SIOPE guideline: Clinical Management of Radiotherapy in Atypical Teratoid/Rhabdoid Tumors (AT/RTs)**

Beate Timmermann<sup>1</sup>, Claire Alapetite<sup>2</sup>, Karin Dieckmann<sup>3</sup>, Rolf-Dieter Kortmann<sup>1,4</sup>, Yasmin Lassen-Ramshad<sup>5</sup>, John H. Maduro<sup>6,7</sup>, Monica Ramos Albiac<sup>8</sup>, Umberto Ricardi<sup>9</sup>, Damien C. Weber<sup>10,11</sup>

<sup>1</sup>Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Germany, German Cancer Consortium (DKTK)

<sup>2</sup>Department of Radiation Oncology and Proton Therapy Center, Institut Curie, Paris-Orsay, France

<sup>3</sup>Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria

<sup>4</sup>University of Leipzig Medical Center, Leipzig, Germany

<sup>5</sup>Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

<sup>6</sup> Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands

<sup>7</sup>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

<sup>8</sup>Department of Radiation Oncology, Hospital Vall d'Hebron, Barcelona, Spain

<sup>9</sup> Department of Oncology, University of Turin, Italy

<sup>10</sup>Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen-PSI, Switzerland

<sup>11</sup>Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland

Keywords: atypical teratoid rhabdoid tumor, radiotherapy, brain tumor, children

Corresponding author: Beate Timmermann, Department of Particle Therapy, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany, email: [beate.timmermann@uk-essen.de](mailto:beate.timmermann@uk-essen.de)

# **ESTRO-SIOPE guideline: Clinical Management of Radiotherapy in Atypical Teratoid/Rhabdoid Tumors (AT/RTs)**

Beate Timmermann<sup>1</sup>, Claire Alapetite<sup>2</sup>, Karin Dieckmann<sup>3</sup>, Rolf-Dieter Kortmann<sup>1,4</sup>, Yasmin Lassen-Ramshad<sup>5</sup>, John H. Maduro<sup>6,7</sup>, Monica Ramos Albiac<sup>8</sup>, Umberto Ricardi<sup>9</sup>, Damien C. Weber<sup>10,11</sup>

<sup>1</sup>Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Germany, German Cancer Consortium (DKTK)

<sup>2</sup>Department of Radiation Oncology and Proton Therapy Center, Institut Curie, Paris-Orsay, France

<sup>3</sup>Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria

<sup>4</sup>University of Leipzig Medical Center, Leipzig, Germany

<sup>5</sup>Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

<sup>6</sup> Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands

<sup>7</sup>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

<sup>8</sup>Department of Radiation Oncology, Hospital Vall d'Hebron, Barcelona, Spain

<sup>9</sup> Department of Oncology, University of Turin, Italy

<sup>10</sup>Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen-PSI, Switzerland

<sup>11</sup>Department of Radiation Oncology. Inselspital, Bern University Hospital, University of Bern, Switzerland

Keywords: atypical teratoid rhabdoid tumor, radiotherapy, brain tumor, children

Corresponding author: Beate Timmermann, Department of Particle Therapy, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany, email: [beate.timmermann@uk-essen.de](mailto:beate.timmermann@uk-essen.de)

## Abstract

### Background and purpose

Treatment of patients with atypical teratoid/rhabdoid (AT/RT) is challenging, especially when very young (below the age of three years). Radiotherapy (RT) is part of a complex trimodality therapy. The purpose of this guideline is to provide appropriate recommendations for RT in the clinical management of patients not enrolled in clinical trials.

### Materials and methods

Nine European experts were nominated to form a European Society for Radiotherapy and Oncology (ESTRO) guideline committee. A systematic literature search was conducted in PubMed/MEDLINE and Web of Science. They discussed and analyzed the evidence concerning the role of RT in the clinical management of AT/RT.

### Results

Recommendations on diagnostic imaging, therapeutic principles, RT considerations regarding timing, dose, techniques, target volume definitions, dose constraints of radiation-sensitive organs at risk, concomitant chemotherapy, and follow-up were considered. Treating children with AT/RT within the framework of prospective trials or prospective registries is of utmost importance.

### Conclusion

The present guideline summarizes the evidence and clinical-based recommendations for RT in patients with AT/RT. Prospective clinical trials and international, large registries evaluating modern treatment approaches will contribute to a better understanding of the best treatment for these children in future.

## Introduction

Atypical teratoid/rhabdoid tumors (AT/RT) are tumors of the central nervous system (CNS) most commonly diagnosed in very young children [1-5], with most (70-80%) tumors found in children under three years of age [6, 7]. The German Childhood Cancer Registry reported that the median age at diagnosis was 18 months [8]. These rare embryonal tumors are locally aggressive and one of the most malignant CNS tumors. Also, they spread throughout the CNS by cerebrospinal fluid (CSF). Up to one-third of the patients have disseminated disease in the brain or spinal canal or both at diagnosis [9, 10]. AT/RT are characterized by alterations of SWItch/sucrose nonfermentable related, matrix associated, actin dependent regulator of chromatin, subfamily B (SMARCB1) gene or less frequently of SMARCA4 [11, 12], and cover three distinct molecular subgroups (tyrosinase (TYR), myelocytomatosis oncogene (MYC), sonic hedgehog (SHH)) [13]. Diagnosis at very young age, anatomically challenging sites and complex treatment approaches make clinical management of patients with AT/RT challenging. These tumors are usually treated with surgery, radiotherapy (RT), and chemotherapy (CTx). Clinical results come from small series reporting the children's outcome treated according to various multimodality regimes. Despite a multimodality therapeutic approach, AT/RT are associated, however with a poor prognosis. The mean survival time ranges from 6 to 18 months [1, 9, 14]. The North American AT/RT registry has reported one of the largest cohorts consisting of 42 children. All children received post-operative CTx, 31% received RT, 38% intrathecal CTx, and 31% stem-cell rescue. The median event-free survival (EFS) and overall survival (OS) were 10.0 and 16.8 months, respectively [15]. In a recently published large retrospective study, 47 children were treated between 1999 and 2014 in Taiwan [4]. Older age ( $\geq 3$  years), supra-tentorial site, and treatment with CTx, RT, or both were significantly associated with a better survival. Molecular profiling was not done in both these studies. A prospective US study reporting the results of the 'Head Start (HS) I/II' trials, assessing the role of induction CTx, with or without high-dose methotrexate, and consolidation with autologous hematopoietic progenitor cell rescue reported an EFS of 6 and 12 months for HS I and II, respectively [16]. These earlier studies highlight the overall poor outcome of these patients regardless of therapeutic strategies. However, modern diagnostic techniques and therapy strategies may have contributed to improvements in clinical outcomes. The prospective ACNS0333 study with 65 patients illustrated the dramatic progress of treatment concepts over the last decades. EFS in patients  $<36$  months of age were significantly improved with the modern treatment concept approaches compared with historical treatment approaches which did not include applying RT for all patients or methotrexate and high-dose CTx [17]. The European Registry for rhabdoid tumors (EU-RHAB) recommended combination CTx therapy with neurosurgery and conventional, intraventricular, and high-dose CTx with stem-cell rescue or RT [18]. Different prognostic factors, such as complete remission, TYR subgroup, age, and RT have been described [19, 20]. The EU-RHAB revealed that high-dose CTx did not show any advantage over conventional CTx, while RT (on univariate analysis) had a significant impact [19]. A recently published analysis of a large group of patients of EU-RHAB and its precursors (n=186) confirmed RT as a prognostic factor for outcome [21]. The current multinational trial SIOPE ATRT01 (EudraCT 2018-003335-29) evaluates the non-inferiority of three courses of high-dose CTx compared to focal RT as consolidation therapy [22].

Today's imaging techniques improve diagnostic findings and target delineation. Modern RT offers a variety of innovative conformal techniques that significantly spare normal tissues. However, homogenous approaches for patients not enrolled in clinical trials are missing. The purpose of this guideline is to provide recommendations on the clinical management of RT in patients with AT/RT. It includes a European consensus on diagnostic imaging, therapeutic principles, RT considerations regarding timing, dose concepts, techniques, target volume

definitions, dose constraints of radiation-sensitive organs at risk (OAR), concomitant CTx, and follow-up care. It defines the current hands-on approach for radiation oncologists treating patients affected by AT/RT.

## **Methods & materials**

The guideline committee of the European Society for Radiotherapy and Oncology (ESTRO) nominated nine experts to develop a joint guideline of the ESTRO and the SIOPE (European Society of Paediatric Oncology) regarding clinical management of radiotherapy in AT/RT. The authors were European clinical and scientific experts in pediatric radiation oncology, being members of the ESTRO (n=8), SIOPE (n=7), the Paediatric Radiation Oncology Society (PROS; n=7), and the SIOP Brain Tumor Group (SIOP BTG; n=5). A systematic literature search was conducted during November 2021 using PubMed/MEDLINE for articles and Web of Science for meeting abstracts. Medical Subjects Headings (MeSH) terms and free text words were used. The search included keywords for the term "AT/RT in children" and the intervention "radiotherapy" combined with further specific RT terms ("organs at Risk", "delineation", "contouring", "margin", "dose constraints", "tolerance dose", "radiation tolerance", "target volume", "gross tumor volume", "clinical target volume", "planning target volume", "timing"). The full search strategy is displayed in Suppl. 1. In PubMed, filters were not used. In Web of Science, the search was limited to only meeting abstracts since 2015. In a title screening, results were selected if papers contained data on AT/RT, and English texts were available. The search detected 260 and 42 results in PubMed and Web of Science, respectively. After the screening, 195 papers and 42 meeting abstracts were available. The bibliography was supplemented by existing guidelines as well as recommendations on target delineation and dose constraints for pediatric brain tumors. Additionally, available AT/RT protocols containing RT applications were used. High-quality systematic reviews, meta-analyses, randomized controlled trials, and cohort studies were used to ensure evidence-based statements.

The development of this guideline was based on the ESTRO Guideline Committee procedure policy [23]. The recommendations are a consensus of the authors developed in four quarterly discussion processes and a final voting online survey. They are based on the evidence and experts' perspectives of currently accepted treatment approaches for patients with AT/RT. Respective recommendations are summarized and highlighted in the text. This guideline passed a mandatory ESTRO internal review.

## **Diagnosis, staging, radiology & molecular findings**

The imaging appearance of AT/RT could be heterogeneous, but several features arise a suspicion of diagnosis and point to specific molecular subtypes. Imaging should be done according to the protocol of the SIOPE Brain Tumour Imaging Group to ensure a high standard and image quality [24]. It is strongly recommended to involve reference pathologists and radiologists for accurate diagnosis, staging, and molecular subtyping.

### *Diagnostic imaging*

AT/RT are predominately located in the supratentorial or infratentorial brain, but can also affect the spinal cord. Supratentorially, they may be centred in basal ganglia, white matter, and cortex.

Intraventricular locations are also possible. In the posterior fossa, two locations are classical: the cerebellopontine angle, or centred in the quadrigeminal cistern, which may extend supratentorially through the tentorial incisure. Often large on the discovery, AT/RT harbors irregular but well-limited contours, possibly perilesional edema, frequent calcifications or hemorrhage. They may present with bony erosion [25]. AT/RT display heterogeneous hypointensity on T1-weighted images, and heterogeneous hyper-intensity on T2-weighted images. Contrast enhancement is present most of the time. Central cystic necrosis is suggestive of the diagnosis, and peripheral cysts are possible. AT/RT can also present with calcification. Diffusion is highly restricted in AT/RTs and is a strong clue for diagnosis. On multimodal imaging, arterial spin labeling (ASL) perfusion is very high, except in SHH AT/RT of the quadrigeminal cistern. Spectroscopy shows elevated peak lactate, lipid and choline, very low N-acetylaspartate (NAA) and low myoinositol peaks.

Taken together, an aggressive neoplasm in a child below 18 months of age with certain criteria, such as necrosis, hemorrhage and calcification should always raise the suspicion of an AT/RT.

### *Staging imaging*

Staging work-up will result in classifying the tumor in either localized, or metastatic; with or without post-operative residual tumor and /or presence of synchronous rhabdoid tumor(s). Early postoperative MRI of the tumor region within 72 hours post-surgery is needed. Apart from craniospinal MRI, whole body MRI is recommended for complete staging. At the time of diagnosis, spinal dissemination is already noted in 20-30% [9, 10]. Detection of leptomeningeal metastases in the entire dural sac using MRI should be based mainly on sagittal T1-weighted sequences with contrast enhancement. If there are lesions within the spine suspicious of tumor/metastases, axial gradient echo T1-weighted (2D or 3D) should be performed over the region of interest. In case of doubt, additional high resolution T2-weighted sequences and diffusion-weighted imaging with apparent diffusion coefficient (DWI with ADC) can be helpful. CSF cytology adds to the accuracy of diagnosis of spread and will be performed after spinal MRI. It is recommended to regularly perform re-staging examinations during the therapy course.

### *Pathology and molecular biology*

Analyses of pathological and molecular characteristics is highly recommended for diagnosis. Since WHO classification 2016 [26], inactivation of SMARCB1 gene (95%) or SMARCA4 (5%) with corresponding loss of nuclear protein product integrase interactor (INI)-1 is a requisite for AT/RT diagnosis. The molecular subgroups TYR-, SHH- and MYC-AT/RT based on different tumor DNA methylation and transcriptome findings and are associated with distinct molecular mechanisms driving oncogenesis.

### *Molecular / radiologic correlations*

Indicator of tumor molecular subtypes is tumor location: TYR-AT/RTs most commonly arise in the cerebellopontine angle, being exophytic from the middle cerebellar peduncle or the cerebellar hemispheres; SHH-ATRTs have two classical locations: either in the posterior fossa in the quadrigeminal cistern (SHH-2) and the supra-tentorial area (SHH-1), or in the basal ganglia (with tumors often extending far beyond); MYC-ATRTs in the posterior fossa are extra-axial (internal auditory canal, jugular foramen, cranial nerves), while in the supratentorial brain they are typically cortical. Intraventricular tumors are also possible, found in all subgroups.



*Germline Alterations*

Germline alterations (rhabdoid tumor predisposition syndrome) are reported in 10-35% of patients with AT/RT and correlate with young age at diagnosis (<12 months), and development of synchronous tumors as well as more aggressive clinical course and poorer prognosis compared to sporadic rhabdoid tumors [27]. Therefore, blood or tissue analyses concerning germline alterations is recommended to assess individual risk profile.

***ESTRO recommendations on clinical management of RT in AT/RT***  
**Diagnosis**

- In cranial tumors, diagnostic imaging requires brain MRI with T1-weighted images (without and with contrast enhancement), T2 weighted images, FLAIR and diffusion weighted images.
- In addition, complete staging (spinal MRI and CSF cytology) is mandatory to verify
  - localized or metastatic disease.
  - with or without post-operative residual tumor.
- In spinal primary tumor, regular spinal and cranial MRI is required.
- Involvement of reference pathologists, reference radiologists, and human geneticists is highly recommended.
- Early postoperative MRI of the tumor region within 72 hours post-surgery is needed.
- Regular re-staging examinations during therapy course are recommended.

**Therapeutic principles**

Treatment of AT/RT is very challenging due to the low incidence of disease and complexity of care. Therefore, the therapeutic approach should be discussed and decided within a multidisciplinary team of specialists (pediatric oncologists, surgeons, pathologists, radiologists, radiation oncologists, and clinical nurse specialists). The care is preferably centralized in experienced, specialized pediatric oncology clinics including referrals networks. To ensure high-quality approach, treatment within prospective trials or international registries is highly encouraged. The standard of care should be applied, if there is not an open trial or registry or the respective inclusion criteria are not met. So far, different treatment strategies are used. Table 1 lists previous and current treatment protocols containing RT in AT/RT.

Current treatment approach in AT/RT should be trimodal (surgery, CTx, and RT). Besides age and molecular subtype, maximum safe resection is the most important prognostic factor. For some patients multiple surgeries are needed. CTx is usually administered as multi-drug treatment, partly intrathecal. Some approaches use high-dose CTx with methotrexate combined with stem-cell rescue. The use of RT remains controversial. For risk- and age-adjusted intensive therapy, RT should be considered and discussed individually in all cases. However, some multimodality treatment studies including high-dose CTx with stem-cell transplantation have shown that patients can survive even when not having received RT [16, 28, 29].

Treatment and care of AT/RT is complex, not at least because of the patients' very young age. Besides the three modalities (surgery, CTx, and RT), additional applications and surgical interventions (ventriculoperitoneal shunt, Omay/Rickham reservoir) may be required. An



affiliated children's clinic is needed for administration of concomitant CTx and treating possibly serious complications during RT (e.g. shunt infections, neutropenia, high-grade mucositis requiring pain medication, and need for enteral feeding). Furthermore, sedation is required for imaging and RT when affected children are too young to cooperate. This procedure enables accurate treatment delivery of RT. Preferably, it is to be performed by an experienced anesthesiological team specialized in pediatric/infant anesthesia. General anesthesia with deep sedation is obtained. Frequent sedation is usually well-tolerated [30-32]. The need of anesthesia during RT treatment preparations or performance, might be not only a question of age of the child under 5-7 years, but for older children as well. Agitation, anxiety, and compliance problems may affect older children as well, especially in the case of children with neurocognitive deficits when they are away from their parents. Hence, anesthesia may be unavoidable in such cases. Additional behavioral therapy may be useful to help children to cooperate during RT and neuroimaging.

***ESTRO recommendations on clinical management of RT in AT/RT***  
**Therapeutic principles**

- Decision on treatment approach should be done after discussion in a multidisciplinary tumor board.
- Treatment should be age- and risk-adapted.
- In principle, three modalities (surgery, CTx, and RT) can be offered. However, the role of RT has to be discussed according to patient's age.
- In case of residual disease at time of RT, resectability should be re-evaluated.
- Care should be performed in specialized clinics (incl. children's clinic and anesthesia team).
- Enrolment of patients in clinical trials and international registries is strongly recommended.

**Timing and sequencing of radiotherapy within multimodality treatment strategy**

The best time for introducing RT in the treatment of AT/RT is under study. Historically, for patients < 36 months old, schedules of intensive CTx including autologous stem-cell transplantation and avoidance of RT have been used. Although the available evidence shows early RT to be beneficial in the treatment of AT/RT, there is reluctance to irradiate very young children because of the neurocognitive and neuroendocrine implications in this age group. Most treatment protocols have attempted to either restrict the use of RT to salvage situations or to delay the treatment until the brain is more mature. Thus, RT is not offered in all protocols, and craniospinal irradiation (CSI) is offered only to children older than three years and to those with CNS dissemination at diagnosis. Focal RT seems to be more acceptable and can also be offered to younger children (below 12 months of age), if considered appropriate, e.g. in palliative settings. Several studies have shown that multimodality therapy including surgery, intensive multidrug systemic treatment and RT yield a better survival [1, 33-38] than if RT is omitted from the primary treatment. This has also been shown in infants [39]. Early RT soon after surgery seems to be beneficial [40-42] because local recurrences often occur already during induction CTx [20, 43-45]. A current pooled analysis reviewing 501 patients (53.1% treated

with RT) highlights the potential benefit of adjuvant RT despite the potential risk of toxicities in younger children (median age 2.2 years) [37]. The 1-, 3-, and 5-year OS rates were 78.8%, 51.0%, and 43.7% with RT compared to 32.2%, 18.6%, and 15.9% without RT, respectively. RT was an independent prognostic factor for OS (hazard ratio (HR) 0.295,  $p < 0.001$ ) [37]. A reasonable strategy to avoid part of neurotoxicity in very young children is to perform focal irradiation after surgery and induction CTx, as published by Reddy et al [17]. In this COG's trial conducted to examine the efficacy and safety of intensive post-operative CTx and focal irradiation [17], focal irradiation was scheduled at the end of consolidation treatment in the younger patients group ( $< 6$  months in infratentorial M0,  $< 12$  months in supratentorial M0) and after induction CTx and before consolidation CTx in M0 patients older than this age. In this analysis, timing of radiation (post-induction vs. post-consolidation) did not affect survival (4-year OS rate 49% vs. 48%) and RT was better tolerated in the group of focal irradiation after the consolidation CTx, than in the cohort receiving early RT after induction CTx. They reported two deaths attributed to CNS necrosis (at 49 and 494 days after completion of protocol therapy) in the last mentioned group [17].

The European strategy is to give RT as early as possible, after surgery for patients older than 18 months, or after induction CTx for patients younger than 18 months [18]. Children below the age of 18 months should only be irradiated under particular circumstances depending on age, tumor localization, tumor extent, progression disease, and available RT technique. The current randomized study SIOPE ATRT01 provides the use of RT from the age of 12 months [46]; the strategy includes surgery, and induction CTx followed by consolidation therapy (high-dose CTx vs. RT).

Application of CSI varies depending on age. EU-RHAB recommended CSI in metastatic disease from age  $> 18$  months [18]. According to COG and SIOPE, CSI is applied in metastatic disease for children older than  $> 36$  months [17, 46]. In contrast, St Jude Children's Research Hospital is using prophylactic CSI in non-metastatic disease from the age of 36 months [7, 9]. To date, it is unclear whether CSI is indicated in non-metastatic disease, and therefore needs to be further investigated in future trials.

***ESTRO recommendations on clinical management of RT in AT/RT***  
**Timing of radiotherapy**

- In children above the age of 3 years ( $\geq 36$  months) RT is part of first-line multimodality treatment.
- For non-metastatic disease, focal RT is recommended for children older than 12-18 months.
- Age- and risk-adapted RT can be applied even in children younger than 12-18 months after multidisciplinary tumor board discussion.

### **Dose and volume concept of radiotherapy**

Historically, ATRT were treated like medulloblastoma. Due to the young age of patients and associated toxicity more risk adapted multimodality strategies has been pursued. The pattern of failure reported in different series displays local, distant, and combined events [2, 17, 47, 48].

Some studies suggested that CSF spread is common at relapse [34, 49]. Although, one study reported the benefit of preventive CSI [50], another showed that therapeutic CSI for M+ patients did not improve outcome [28]. Whether focal RT in non-metastatic disease is sufficient instead of CSI, remains still unclear. Most recurrences in children with localized disease are reported to be local [1] and German series indicated no impact of CSI on prognosis [21]. Therefore, the current recommendation is early focal RT in non-metastatic disease [51]. Early focal RT resulted in improved survival as compared to historical cohorts with 4-year OS of 43% in the ACNS0333 trial [17, 21, 45, 51].

The recommended dose to the primary site is 54 Gy in fractions of 1.8 Gy [17, 18, 52]. At a very young age (below 36 months), total dose may be reduced to 50.4 Gy [17, 52]. In the case of macroscopic residual disease, a boost of 5.4 Gy in 3 fractions could be considered up to a cumulative dose of 59.4 Gy [18, 46].

Children aged 36 months or older with leptomeningeal metastatic disease are treated with CSI to a dose of 35.2-36.0 Gy in 20-22 fractions, followed by a boost up to 54 Gy to the primary site and 45-50.4 Gy to the sites of persistent metastatic spinal and cranial disease [17, 18, 53]. For children aged 12 to 36 months with metastatic disease, there is still a debate as to whether CSI should be applied. The EU-RHAB protocol recommends 24 Gy in fractions of 1.6 Gy CSI for children aged up to 18 months with metastatic disease [18], the ACNS0333 recommends 23.4 Gy CSI in fractions of 1.8 Gy for children aged 12 to 36 months [17] and in the most recent SIOPE protocol no CSI is advised for patients below 36 months of age within first line therapy [46]. Individual decision to treat craniospinal axis in children below 36 months should be based on multidisciplinary tumor board recommendation and after discussion with parents and carers. It is highly recommended to treat patients with AT/RT either in trials or in international registries.

***ESTRO recommendations on clinical management of RT in AT/RT***  
**Dose and volume concept**

- Focal RT has to be applied in non-metastatic disease (age  $\geq$  12-18 months).
- CSI should be considered only in metastatic disease (depending on age).
- Total recommended dose to primary site is 54 Gy (single dose 1.8 Gy). Dose reduction to 50.4 Gy can only be considered individually (e.g. in age below 36 months).
- The recommended CSI dose (for children  $>$  36 months) is 35.2-36.0 Gy with single doses of 1.6-1.8 Gy.
- Recommendation for CSI in children below 36 months of age should be only made after individual tumor board discussion. If required, the dose may be reduced to 23.4/24 Gy.
- Recommended total boost dose to persistent spinal and cranial metastasis is 45-50.4 Gy.

### **Radiotherapy treatment techniques**

The choice of treatment modality (protons or photons) is a matter of debate [54]. Several authors suggest that proton beam therapy might be beneficial for this disease [14, 20, 34, 36, 37, 52] as this treatment is highly conformal, has a lower integral dose and a better sparing of the normal brain than with traditional photon RT [14]. In the recently reported ACNS0333 trial, both photon and proton therapy were used. For both treatment modalities similar tumor control was

reported. The risk of imaging changes and radiation necrosis was comparable for both types of RT [17]. Institutional outcome series have been reported for proton techniques [2, 14, 49, 55]. To minimize the volume of irradiated brain, especially for young aged patients, it is recommended, if available, to preferably use proton therapy or highly conformal intensity/volumetric modulated radiation techniques. Beside the multidisciplinary framework, also inter-departmental collaboration is important, in which centers with high degree of expertise can offer assistance and review services. Figure 1 shows a comparison between a photon and proton treatment plan for focal irradiation.

Stereotactic radiosurgery for the treatment of AT/RT either using a Gamma Knife, Cyberknife or linac-based radiosurgery approach can be considered as a boost for residual tumor after fractionated treatment or as a salvage therapy. Some experiences in radiosurgery for patients with AT/RT have been reported [56-58]. Spina et al. achieved a local control rate of 66.7% after radiosurgery, but 33.3% of patients developed craniospinal tumor dissemination [56].

***ESTRO recommendations on clinical management of RT in AT/RT***  
**Treatment techniques and modalities**

- Proton therapy is the preferred radiotherapy technique. Alternatively, highly conformal intensity/volumetric modulated techniques may be considered, if proton therapy is not available.
- Treatment in specialized RT centers within a multidisciplinary environment is strongly recommended.

### **Target delineation, imaging, planning details, tolerance doses**

Pre- and post-operative MRI according to SIOPE MRI guideline [24] (T1-weighted with contrast, T2-weighted and FLAIR sequences, and diffusion-weighted imaging) should be preferred for treatment planning. Co-registered MRI immediately before RT should be used for computed tomography scan (CT) planning. The target delineation should be based on co-registration of the planning CT and diagnostic MRI. Usually, a planning MRI and preoperative MRIs are used to properly identify the tumor bed and small residues. Contrast enhancement is not always present in the lesions. Tumor extensions through the skull base may be better visible on T2 sequences. This sequence can therefore be beneficial or a second plane with thin slices 2D T2 TSE.

In relation to the primary tumor location, the tumor bed should be delineated by including the parts of the brain that the tumor has been in contact with, by taking into consideration that a shift of these structures after surgery can have occurred. Any residual macroscopic tumor needs to be included into the tumor bed. In case of focal RT, the gross tumor volume (GTV) includes the tumor bed and any residual tumor. The pre-operative imaging defines the areas initially involved with disease. The clinical target volume (CTV) includes the GTV and is limited to the confines of the bony calvarium, falx and tentorium or extend up to but not beyond neuroanatomical structures. The CTV margin should be defined according to the protocol used. The recommended CTV margin to the reconstructed tumor bed is 10 mm and respective anatomical boundaries. It will be a matter of future trials if the margin can be further reduced to 5 mm similar to strategies for ependymoma.

In case of CSI, the technology selected for CSI should ensure an optimal dose homogeneity within the entire spinal canal thecal sac = CTV). The whole brain CTV should include the entire frontal lobe and cribriform plate region. Measures to prevent asymmetric growth of the vertebral bodies should be taken into account [59]. The PTV is defined as the CTV plus an additional margin depending on geometric precision of the technology applied both for CSI and focal RT. Target volume delineation should be done according to the SIOPE brain tumor group consensus guideline [60].

The co-registered MRI is also beneficial for delineation of organs at risk (OAR). Published CT and MRI based atlas offer guidance, even if partly addressing adult patients [61-63]. Doses to OARs need to take the young age of the patient into consideration and are often lower than constraints usually applied for adults. The PENTEC group has recently published dose constraints for selected OARs in the pediatric population [64]. To prevent neurocognitive deficits the dose to the normal brain should be restricted as much as possible. Dose constraints recommendations are summarized in table 2.

***ESTRO recommendations on clinical management of RT in AT/RT***

**Target delineation, imaging, planning details, and tolerance doses**

- For delineation, pre-and post-operative MRI according to SIOPE MRI guideline should be used.
- For focal RT, the GTV should include the tumor bed and residual tumor identified on the brain MRIs.
- For focal RT, the recommended CTV margin to the GTV is 10 mm, taking into account the anatomical boundaries.
- The PTV is defined as the CTV plus an additional margin depending on geometric precision of the technology applied both for CSI and focal RT by the institution.

### **Quality assurance**

Quality assurance is essential in order to obtain optimal treatment results and avoid unnecessary dose-burden to normal tissue [65, 66]. In medulloblastoma, inadequate treatment planning showed a negative impact on tumor control and outcome, requiring quality control procedures for treatment planning before starting RT in prospective treatment protocols [65, 67]. Quality control is based on extensive information before RT planning and typically covers the review of RT treatment strategy, target delineation, dose planning, and reproducibility of the treatment. Recent data revealed that with the introduction of intensity modulated RT (IMRT), volumetric intensity modulated arc therapy (VMAT) and proton therapy integrating MRI, high rates of protocol deviations including identification and coverage of GTV and CTV as well as dose homogeneity within PTV and CTV were observed both in CSI and focal RT. Past evaluation criteria for quality control cannot be applied and need to be revised, including the assessment about their clinical relevance or acceptance, respectively [65, 67]. If the patient is not included in a prospective clinical protocol, particular attention has to be directed to all treatment planning parameters and their possible pitfalls in AT/RT. A prospective, independent QA program, including a review of the RT treatment plan is recommended, at least in a peer review process.



The QUARTET group has set up a RT quality assurance guideline for the ongoing SIOPE ATRT01 trial [46].

***ESTRO recommendations on clinical management of RT in AT/RT***

**Quality assurance**

- High vulnerability of this particular patient cohort has to be considered and dose tolerances of OARs have to be respected according to the recommendations.
- High-quality of RT planning and application has to be assured, preferably by an external QA program, but as a minimal requirement by peer review process.

**Toxicity, interaction with chemotherapy, and supportive therapy during radiotherapy**

For maximal tumor control, the aim is to apply planned RT without interruptions and with concomitant CTx. Daily sedation has to be ensured, if necessary. However, acute toxicity in children with AT/RT receiving dose-intense CTx can occur, especially when receiving CSI. Main side-effect is bone marrow suppression, with changes in the blood count. Weight loss, nausea, vomiting, anorexia, discomfort, fatigue, and headache may occur. At the commencement of RT, an adequate blood count should be ensured, with a hemoglobin level of above 10 g/dl, neutrophils > 1.000 and platelets > 50.000. During RT (cranial/craniospinal), weekly blood counts are necessary to monitor the risk of thrombocytopenia and anemia in order to substitute thrombocytes and erythrocytes if necessary; low number of neutrophils may increase the risk of infections, and may require antibiotics. During CSI, concurrent CTx must be avoided. After RT of the neuroaxis (while boosting the tumor bed) concomitant CTx may be considered [68]. Analyses of combined treatment strategies should be evaluated in future studies.

Interactions between RT and certain CTx agents can result in a high risk of toxicities, necessitating treatment interruptions. Therefore, precautions should be taken during concomitant CTx. Actinomycin D and Doxorubicin should be avoided at least two weeks before RT, during RT, and 2-4 weeks after RT. Furthermore, intrathecal and intraventricular CTx should not be given during and after RT. CTx doses during RT can be reduced depending on previous tolerance. If necessary, G-CSF should be given to avoid neutropenia. For patients with serious complications in pre-RT CTx, concomitant CTx should be avoided.

An additional side effect of CSI can be severe mucositis with swallowing problems and loss of weight. Weekly assessment of weight and dietetic advice are essential to avoid significant weight loss. Non-spicy and salt reduced soft or fluid nutrition can be helpful in case of minor symptoms. In case of increasing esophagitis and progressive weight loss, substitutions of calories or fluids may require a naso-gastric tube or intravenous nutrition. The substitution of fluids and calories has to be calculated according to the body weight of the patient. Anti-inflammatory and anti-fungal drugs and analgesics can reduce symptoms of esophagitis. Usually, the symptoms of acute esophagitis completely resolve 7-10 days after the completion of RT.

Headache, especially during the first days of treatment, and nausea (combined with or without vomiting) are often reported as acute side effects. Anti-emetics, often combined with



dexamethasone, are recommended to reduce these symptoms. Dose of steroids have to be according to the age and weight of patients. The duration of corticosteroid treatment should be as short as possible. Anti-emetics can be given up to four times a day.

***ESTRO recommendations on clinical management of RT in AT/RT***  
**Toxicity with chemotherapy interaction**

- CTx need to be tailored in order to avoid interruptions of RT.
- Interdisciplinary care during RT is essential to manage side-effects and to modify therapy. Blood count should be adequate at the start of RT.
- Weekly assessment of weight and blood counts during RT are strongly recommended.
- No administration of
  - Actinomycin D and Doxorubicin before (at least 2 weeks), during, and after (2-4 weeks) RT.
  - intrathecal and intraventricular CTx concomitant to RT.
  - concomitant i.v. CTx while CSI, but can be considered during focal RT.
- i.v. CTx dose reduction can be discussed with the pediatric oncologist.
- Best supportive care has to be offered according to side-effects (e.g. nausea, headache, etc.).

**Follow up and aftercare (perspective of radiotherapy)**

The overall prognosis of children with AT/RT is grim, but is improving with multi-modality treatments [69]. Long-term survival may be seen in selected children with possibly favourable DNA methylation and/or gene expression signatures (possibly toddlers with supratentorial tumors and ATRT-SHH subgroup [17, 70]). Late (i.e.  $\geq 36$  months) recurrences, distant or local, have been observed in prospective [17] and retrospective [2, 71, 72] studies. Although successful salvage rates for those with recurring or progressing disease is low [73], survivors of AT/RT may benefit from clinical and/or radiological follow-up. Serial radiological imaging studies of the brain and spinal canal should be done every 3-4 months after the end of treatment, or earlier if clinically indicated, for 2-3 years, and at least bi-annually thereafter. Regarding imaging, the protocol of the SIOPE Brain Tumour Imaging Group the SIOPE study protocol should be respected during follow-up [24, 53]. Clinical examinations should also be performed regularly in these growing survivors. Of note, these young children with AT/RT undergo intensive treatment, with a rate of treatment-related deaths up to 6-11.9% [17, 72], and may also be at risk for clinically relevant treatment-induced serious events. A structured follow-up protocol will enable health professionals to monitor any such toxicity, not limited but including cognitive, motor, visual, and hearing impairment and propose appropriate therapies if appropriate. Of noteworthy, leukoencephalopathy was observed on follow-up imaging in a substantial number of patients who had treatment for brain tumors, particularly in those exposed to intrathecal methotrexate and had measurable decrements in measures of intelligence [74]. It is also advisable to assess the quality of life (QoL) using proxy-questionnaires in surviving children, as a substantial number of patients show some decrease in QoL scoring, especially in the social domain after therapy [2].

***ESTRO recommendations on clinical management of RT in AT/RT*****Follow up and aftercare**

- Clinical and/or radiological follow up is to be performed by a multidisciplinary team.
- MRIs should be scheduled at least every 3-4 months for 2-3 years, thereafter bi-annually.
- Structured follow up protocol is recommended in order to monitor possible adverse events incl. health related quality of life.

**Limitations**

Given the rarity of the disease, existing data is scarce. Small cohorts and mostly retrospective character of analyses limit the evidence level. Recognizing there are different approaches, this guideline summarizes evidence-based recommendations from established study protocols. Further recommendations arise from consensus of the attending experts based on clinical practice.

**Conclusions**

The present ESTRO guideline provides evidence and expert opinion-based recommendations of management of RT in patients with AT/RT. This aggressive and challenging disease demands complex treatment strategies. It occurs in very young children and is associated with a potentially high risk of treatment-related late toxicities. However, RT is an important element of the multimodality treatment approach. It is highly encouraged to treat children with AT/RT within a multidisciplinary setting according to clinical trials or registries in highly specialized centers. Furthermore, prospective data collection and evaluation should be centralized. Prospective clinical trials and international, large registries evaluating modern treatment approaches would contribute to a better understanding of the optimal treatment approach for children with AT/RT. As several questions in the RT field remain open, it will be crucial to cover questions concerning RT within future multidisciplinary treatment studies.

## Figure

Figure 1. Plan comparison for focal irradiation of a 1-year-old patient with localized supratentorial AT/RT. The upper panel shows the dose distribution in color-wash for doses 10 - 58 Gy (RBE). The axial and sagittal figure on the left side are from a 3 fields pencil beam scanning proton plan (PBS), the axial and sagittal figure on the right side are from a 3 arc volumetric modulated arc therapy photon plan (VMAT). In the lower panel the dose-volume-histogram for selected structures (green: left hippocampus, orange: whole brain, yellow: pituitary gland, red: clinical target volume), squares represent the proton plan and triangles the photon plan.

## Tables

Table 1. Overview of clinical protocols for the treatment of AT/RT.

Table 2. Recommendations on dose constraints.

## Acknowledgement

We thank Sabine Frisch (West German Proton Therapy Center Essen, Germany) for conducting the literature search, and formal editing and revising the manuscript.

We acknowledge the comprehensive review of this guideline by Thankamma Ajithkumar, Michael Frühwald and Brigitte Bison. We sincerely appreciate their valuable comments and suggestions, which helped improving the quality of the manuscript.

## DISCLAIMER

*ESTRO cannot endorse all statements or opinions made on the guidelines. Regardless of the vast professional knowledge and scientific expertise in the field of radiation oncology that ESTRO possesses, the Society cannot inspect all information to determine the truthfulness, accuracy, reliability, completeness or relevancy thereof. Under no circumstances will ESTRO be held liable for any decision taken or acted upon as a result of reliance on the content of the guidelines.*

*The component information of the guidelines is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the guidelines is done so for solely educational and scientific purposes. ESTRO and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the guidelines. This includes any implied warranties and conditions that may be derived from the aforementioned guidelines.*

## References

1. Packer, R.J., et al., *Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop*. J Pediatr Hematol Oncol, 2002. **24**(5): p. 337-42.

2. Weber, D.C., et al., *Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy*. *J Neurooncol*, 2015. **121**(2): p. 389-97.
3. Burger, P.C., et al., *Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study*. *Am J Surg Pathol*, 1998. **22**(9): p. 1083-92.
4. Liu, Y.L., et al., *Atypical Teratoid/Rhabdoid Tumor in Taiwan: A Nationwide, Population-Based Study*. *Cancers (Basel)*, 2022. **14**(3).
5. Mousa, A., et al., *Atypical Teratoid Rhabdoid Tumors (ATRT): King Faisal Specialist Hospital and Research Centre experience*. *Int J Pediatr Adolesc Med*, 2021. **8**(3): p. 154-159.
6. Lau, C.S., K. Mahendraraj, and R.S. Chamberlain, *Atypical teratoid rhabdoid tumors: a population-based clinical outcomes study involving 174 patients from the Surveillance, Epidemiology, and End Results database (1973-2010)*. *Cancer Manag Res*, 2015. **7**: p. 301-9.
7. Upadhyaya, S.A., et al., *Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials*. *Clin Cancer Res*, 2021. **27**(10): p. 2879-2889.
8. Erdmann, F.K., P.; Grabow, D.; Spix, C. *German Childhood Cancer Registry - Annual Report 2019 (1980-2018)*. Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at University Medical Center of the Johannes Gutenberg University Mainz. 2020.  
[https://www.kinderkrebsregister.de/typo3temp/secure\\_downloads/42507/0/1c5976c2ab8af5b6b388149df7182582a4cd6a39/Buch\\_DKKR\\_Jahresbericht\\_2019\\_komplett.pdf](https://www.kinderkrebsregister.de/typo3temp/secure_downloads/42507/0/1c5976c2ab8af5b6b388149df7182582a4cd6a39/Buch_DKKR_Jahresbericht_2019_komplett.pdf) (last accessed 05.01.2024).
9. Tekautz, T.M., et al., *Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy*. *J Clin Oncol*, 2005. **23**(7): p. 1491-9.
10. Frühwald, M.C., et al., *Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors*. *Neuro Oncol*, 2020. **22**(7): p. 1006-1017.
11. Hasselblatt, M., et al., *High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors*. *Genes Chromosomes Cancer*, 2013. **52**(2): p. 185-90.
12. Hasselblatt, M., et al., *SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis*. *Acta Neuropathol*, 2014. **128**(3): p. 453-6.
13. Johann, P.D., et al., *Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes*. *Cancer Cell*, 2016. **29**(3): p. 379-93.
14. De Amorim Bernstein, K., et al., *Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors*. *Int J Radiat Oncol Biol Phys*, 2013. **86**(1): p. 114-20.
15. Hilden, J.M., et al., *Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry*. *J Clin Oncol*, 2004. **22**(14): p. 2877-84.
16. Gardner, S.L., et al., *Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors*. *Pediatr Blood Cancer*, 2008. **51**(2): p. 235-40.

17. Reddy, A.T., et al., *Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333*. J Clin Oncol, 2020. **38**(11): p. 1175-1185.
  18. *European Rhabdoid Registry - EU-RHAB. A multinational registry for rhabdoid tumors of any anatomical site, Version 5, 2016, available from: [http://www.rhabdoid.de/fileadmin/Daten/Pdfs/EU-RHAB\\_Protokoll\\_Stand\\_08.12.2016.pdf](http://www.rhabdoid.de/fileadmin/Daten/Pdfs/EU-RHAB_Protokoll_Stand_08.12.2016.pdf) (last accessed: 29.11.2022).*
  19. Fruhwald, M.C., et al., *Age and DNA-methylation subgroup as potential independent risk factors for treatment stratification in children with Atypical Teratoid/Rhabdoid Tumors (ATRT)*. Neuro Oncol, 2019.
  20. Bartelheim, K., et al., *Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007*. Cancer Med., 2016. **5**(8): p. 1765-75.
  21. Frisch, S., et al., *Radiation Therapy Plays an Important Role in the Treatment of Atypical Teratoid/Rhabdoid Tumors: Analysis of the EU-RHAB Cohorts and Their Precursors*. Int J Radiat Oncol Biol Phys, 2024.
  22. *SIOPE ATRT01, 2019, available from: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003335-29/DE> (last accessed: 28.12.2022).*
  23. *ESTRO. Guidelines-Committee-policy\_July-2022.pdf.aspx (estro.org), 2022 (last accessed 27.02.2023).*
  24. Avula, S., et al., *European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours*. Childs Nerv Syst, 2021. **37**(8): p. 2497-2508.
  25. Warmuth-Metz, M., et al., *Bone involvement in atypical teratoid/rhabdoid tumors of the CNS*. AJNR Am J Neuroradiol, 2013. **34**(10): p. 2039-42.
  26. Louis, D.N., et al., *The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary*. Acta Neuropathol, 2016. **131**(6): p. 803-20.
  27. Nemes, K., et al., *Rhabdoid Tumor Predisposition Syndrome*, in GeneReviews®, M.P. Adam, et al., Editors. 1993, University of Washington, Seattle
- Copyright © 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.: Seattle (WA).
28. Yamasaki, K., et al., *Clinical characteristics, treatment, and survival outcome in pediatric patients with atypical teratoid/rhabdoid tumors: a retrospective study by the Japan Children's Cancer Group*. J Neurosurg Pediatr, 2020. **25**: p. 111-120.
  29. Lafay-Cousin, L., et al., *Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience*. Eur J Cancer, 2012. **48**(3): p. 353-9.
  30. Clerici, C.A., et al., *Age-appropriate multidisciplinary approach to young children with cancer undergoing radiotherapy: The SIESTA procedure*. Pediatr Blood Cancer, 2021. **68**(1): p. e28650.
  31. Gårdling, J., et al., *Age-appropriate preparations for children with cancer undergoing radiotherapy: A feasibility study*. J Child Health Care, 2017. **21**(4): p. 370-380.
  32. Langemeyer, V., et al., *Evaluation of repeated sedation in children during proton beam radiotherapy: Experiences from a large monoinstitutional cohort*. International Journal of Radiation Oncology\*Biophysics, 2022. **114**(5): p. 1069.

33. Ishisaka, E., et al., *Neoadjuvant chemotherapy for atypical teratoid rhabdoid tumors (AT/RTs)*. Childs Nerv Syst, 2020. **36**(4): p. 721-727.
34. Biswas, A., et al., *Atypical teratoid/rhabdoid tumors: challenges and search for solutions*. Cancer Manag Res, 2016. **8**: p. 115-125.
35. Underiner, R.M., et al., *Meta-Analysis of Treatment Modalities in Metastatic Atypical Teratoid/Rhabdoid Tumors in Children*. Pediatr Neurol, 2020. **108**: p. 106-112.
36. Squire, S.E., M.D. Chan, and K.J. Marcus, *Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy*. J Neurooncol, 2007. **81**(1): p. 97-111.
37. Ma, X.J., et al., *Overall Survival of Primary Intracranial Atypical Teratoid Rhabdoid Tumor Following Multimodal Treatment: A Pooled Analysis of Individual Patient Data*. Neurosurg Rev, 2020. **43**(1): p. 281-292.
38. Athale, U.H., et al., *Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies*. J Pediatr Hematol Oncol, 2009. **31**(9): p. 651-63.
39. Lu, V.M., et al., *Age of diagnosis clinically differentiates atypical teratoid/rhabdoid tumors diagnosed below age of 3 years: a database study*. Childs Nerv Syst, 2021. **37**(4): p. 1077-1085.
40. Ma, Y., et al., *Tandem High-dose Chemotherapy without Craniospinal Irradiation in Treatment of Non-metastatic Malignant Brain Tumors in Very Young Children*. J Korean Med Sci, 2020. **35**(48): p. e405.
41. Lee, Y.E., et al., *Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor*. Neuro Oncol, 2017. **19**(8): p. 1079-1087.
42. Yang, W.C., et al., *Effect of early radiotherapy initiation and high-dose chemotherapy on the prognosis of pediatric atypical teratoid rhabdoid tumors in different age groups*. J Neurooncol, 2020. **147**(3): p. 619-631.
43. Sung, K.W., et al., *Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Atypical Teratoid/Rhabdoid Tumor*. Cancer Res Treat, 2016. **48**(4): p. 1408-1419.
44. Zaky, W., et al., *Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience*. Pediatr Blood Cancer, 2014. **61**(1): p. 95-101.
45. Pai Panandiker, A.S., et al., *Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system*. Int J Radiat Oncol Biol Phys, 2012. **82**(5): p. 1756-63.
46. *SIOPE ATRT01 QUARTET Radiotherapy Quality Assurance Guidelines Version 1.1, 2023, personal correspondence*.
47. Benesch, M., et al., *Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort*. Pediatr Blood Cancer, 2020. **67**(1): p. e28022.
48. Chi, S.N., et al., *Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor*. J Clin Oncol, 2009. **27**(3): p. 385-9.
49. McGovern, S.L., et al., *Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system*. Int J Radiat Oncol Biol Phys, 2014. **90**(5): p. 1143-52.



50. Yang, W.C., et al., *Role of early and aggressive post-operative radiation therapy in improving outcome for pediatric central nervous system atypical teratoid/rhabdoid tumor*. *Childs Nerv Syst*, 2019. **35**(6): p. 1013-1020.
51. Fischer-Valuck, B.W., et al., *Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database*. *Cancer*, 2017. **123**(4): p. 682-687.
52. McGovern, S.L., D. Grosshans, and A. Mahajan, *Embryonal brain tumors*. *Cancer J*, 2014. **20**(6): p. 397-402.
53. *SIOPE ATRT01 - An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy. Protocol Version 1.3.1, 2021, personal correspondence.*
54. Seravalli, E., et al., *Dosimetric comparison of five different techniques for craniospinal irradiation across 15 European centers: analysis on behalf of the SIOP-E-BTG (radiotherapy working group)*(J). *Acta Oncol*, 2018. **57**(9): p. 1240-1249.
55. Jazmati, D., et al., *Feasibility of Proton Beam Therapy for Infants with Brain Tumours: Experiences from the Prospective KiProReg Registry Study*. *Clin Oncol (R Coll Radiol)*, 2021.
56. Spina, A., et al., *Does Stereotactic Radiosurgery Positively Impact the Local Control of Atypical Teratoid Rhabdoid Tumors?* *World Neurosurg*, 2017.
57. Ren, Y.M., et al., *Multimodal treatments combined with gamma knife surgery for primary atypical teratoid/rhabdoid tumor of the central nervous system: a single-institute experience of 18 patients*. *Childs Nerv Syst*, 2018. **34**(4): p. 627-638.
58. Giller, C.A., et al., *Robotically guided radiosurgery for children*. *Pediatr Blood Cancer*, 2005. **45**(3): p. 304-10.
59. Hoeben, B.A., et al., *Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group*. *Lancet Oncol.*, 2019. **20**(3): p. e155-e166.
60. Ajithkumar, T., et al., *SIOPE - Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy*. *Radiother Oncol*, 2018. **128**(2): p. 192-197.
61. Eekers, D.B.P., et al., *Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology*. *Radiother Oncol*, 2021. **160**: p. 259-265.
62. Eekers, D.B., et al., *The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology*. *Radiother Oncol*, 2018. **128**(1): p. 37-43.
63. Scocianti, S., et al., *Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist's guide for delineation in everyday practice*. *Radiother Oncol*, 2015. **114**(2): p. 230-8.
64. Mahajan, A., et al., *Neurocognitive Effects and Necrosis in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review*. *Int J Radiat Oncol Biol Phys*, 2021.
65. Dietzsch, S., et al., *Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma : First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial*. *Strahlenther Onkol*, 2021. **197**(8): p. 674-682.

66. Kortmann, R.D., et al., *HIT '91 (prospective, co-operative study for the treatment of malignant brain tumors in childhood): accuracy and acute toxicity of the irradiation of the craniospinal axis. Results of the quality assurance program*. *Strahlenther Onkol*, 1999. **175**(4): p. 162-9.
67. Dietzsch, S., et al., *Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial*. *Strahlenther Onkol*, 2022. **198**(3): p. 282-290.
68. *EU-RHAB, [Simultane Radiochemotherapie bei Patienten mit rhabdoiden Tumoren], 2015, personal correspondance to EU-RHAB group (14.10.2015)*.
69. Reddy, A.T., *Atypical teratoid/rhabdoid tumors of the central nervous system*. *J Neurooncol*, 2005. **75**(3): p. 309-13.
70. Ho, B., et al., *Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus*. *Neuro Oncol*, 2020. **22**(5): p. 613-624.
71. Elsayad, K., et al., *Long-term survival following additive radiotherapy in patients with atypical teratoid rhabdoid tumors*. *Strahlenther Onkol*, 2016. **192**(8): p. 569-81.
72. Park, M., et al., *Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years*. *Cancer Res Treat*, 2021. **53**(2): p. 378-388.
73. Wang, C.H., et al., *Efficacy of temozolomide for recurrent embryonal brain tumors in children*. *Childs Nerv Syst*, 2009. **25**(5): p. 535-41.
74. Rutkowski, S., et al., *Treatment of early childhood medulloblastoma by postoperative chemotherapy alone*. *N Engl J Med*, 2005. **352**(10): p. 978-86.

## Highlights

- Multimodal treatment of children with AT/RT
- Complex therapy in very young children and infants with high-risk tumors
- European guideline regarding radiotherapy in AT/RT
- Challenges and strategies in the clinical management of patients with AT/RT

Table 1. Overview of clinical protocols for the treatment of AT/RT

Acronym	Sponsor	Title	Registration number	St
ACNS0333	Children's Oncology Group	Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in	NCT00653068	Ar re

		Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System		
SJMB03	St. Jude Children's Research Hospital	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid	NCT00085202	Ar
02-294 DFCI	Dana-Farber Cancer Institute	A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor	NCT00084838	C
SJYC07	St. Jude Children's Research Hospital	Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	NCT00602667	Ar
SJATRT	St. Jude Children's Research Hospital	Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT	NCT02114229	R
SIOPE ATRT01	German Paediatric Oncology Group	An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT)  A randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy	EudraCT 2018-003335-29	R
EU-RHAB		European Rhabdoid Registry		O

Table 2. Recommendations on dose constraints

Organ	Mean dose (Gy)	Max dose (D1%) (Gy)	Reference
Brainstem	54	59 (*-63)	[53]
Brainstem center (diameter 2-3mm)	54	56	[53]

Spinal cord (below C1)	50.4	54	[53]
Optic nerve (left and right)	54	54 (*-56)	[53]
Chiasm	54	54 (*-56)	[53]
Cochlea (left and right)	30	45	[53]
Cochlea (left and right), if ototoxic chemotherapy	25	30	[53]
Lens (left and right)	5	7	[53]
Temporal lobe (left and right)	30% Vol. < 25 Gy, 60% Vol. < 20 Gy		[53]
Hippocampus (left and right)	30% Vol. < 30 Gy, 60% Vol. < 25 Gy		[53]
Thyroid	as low as possible	-	[53]
Pituitary	36	-	[53]
Vertebrae for CSI in growing children	Consider dose coverage of full vertebral bodies up to at least 20 Gy in growing children to best avoid significant growth asymmetry		[53]
Brain (necrosis)		58.8-59.8	[64]
Brain (neurocognition, methotrexate effect not included)	D <sub>100%</sub> 18.1 Gy D <sub>50%</sub> 22.2 Gy		[64]

	D <sub>20%</sub> 29.1 Gy	
	D <sub>10%</sub> 35.7 Gy	

\*Only in high-risk scenarios individually according to risk profile and expected feasibility

